Skip to main navigation Skip to search Skip to main content

First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa

  • Ameena E. Goga
  • , Thu Ha Dinh
  • , Debra J. Jackson
  • , Carl Lombard
  • , Kevin P. Delaney
  • , Adrian Puren
  • , Gayle Sherman
  • , Selamawit Woldesenbet
  • , Vundli Ramokolo
  • , Siobhan Crowley
  • , Tanya Doherty
  • , Mickey Chopra
  • , Nathan Shaffer
  • , Yogan Pillay
  • , Wondwossen Lerebo
  • , Wesley Solomon
  • , Nobuntu Noveve
  • , Lucille Heyns
  • , Jazelle Kiewitz
  • , Pumza Mbenenge
  • Madoda Xokwe, Eva Mboweni, Similo Mzolo, Ria Molewa, Rose Hlabangani, Tshawe Ncedana, Nomalipheze Sitawutawu, Faith Nyati, Christalien Husselman, Katherine Robinson, Tsakani Mhlongo, Beverley Singh, Ushmita Patel
  • South African Medical Research Council
  • National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
  • University of the Western Cape
  • National Institute for Communicable Diseases
  • ELMA Philanthropies
  • UNICEF
  • Organisation Mondiale de la Santé
  • Department of Health, Pretoria

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There is a paucity of data on the national population-level effectiveness of preventing mother-tochild transmission (PMTCT) programmes in high-HIVprevalence, resource-limited settings. We assessed national PMTCT impact in South Africa (SA), 2010. Methods: A facility-based survey was conducted using a stratified multistage, cluster sampling design. A nationally representative sample of 10 178 infants aged 4-8 weeks was recruited from 565 clinics. Data collection included caregiver interviews, record reviews and infant dried blood spots to identify HIV-exposed infants (HEI) and HIV-infected infants. During analysis, self-reported antiretroviral (ARV) use was categorised: 1a: triple ARV treatment; 1b: azidothymidine >10 weeks; 2a: azidothymidine ≤10 weeks; 2b: incomplete ARV prophylaxis; 3a: no antenatal ARV and 3b: missing ARV information. Findings were adjusted for non-response, survey design and weighted for live-birth distributions. Results: Nationally, 32% of live infants were HEI; early mother-to-child transmission (MTCT) was 3.5% (95% CI 2.9% to 4.1%). In total 29.4% HEI were born to mothers on triple ARV treatment (category 1a) 55.6% on prophylaxis (1b, 2a, 2b), 9.5% received no antenatal ARV (3a) and 5.5% had missing ARV information (3b). Controlling for other factors groups, 1b and 2a had similar MTCT to 1a (Ref; adjusted OR (AOR) for 1b, 0.98, 0.52 to 1.83; and 2a, 1.31, 0.69 to 2.48). MTCT was higher in group 2b (AOR 3.68, 1.69 to 7.97). Within group 3a, early MTCT was highest among breastfeeding mothers 11.50% (4.67% to 18.33%) for exclusive breast feeding, 11.90% (7.45% to 16.35%) for mixed breast feeding, and 3.45% (0.53% to 6.35%) for no breast feeding). Antiretroviral therapy or >10 weeks prophylaxis negated this difference (MTCT 3.94%, 1.98% to 5.90%; 2.07%, 0.55% to 3.60% and 2.11%, 1.28% to 2.95%, respectively). Conclusions: SA, a high-HIV-prevalence middle income country achieved <5% MTCT by 4-8 weeks post partum. The long-term impact on PMTCT on HIV-free survival needs urgent assessment.

Original languageAmerican English
JournalJournal of Epidemiology and Community Health
Volume69
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Cite this